EUVIMEDEUVIMED entdecken
Crossref

Effect of Sodium-Glucose Cotransporter-2 Inhibitors on the Progression of Aortic Stenosis

Tayyab Shah, Zhiyuan Zhang, Haashim Shah, Alexander C Fanaroff, Ashwin S Nathan, Helen Parise, John Lutz, Lissa Sugeng, Lavanya Bellumkonda, Björn Redfors, Elmir Omerovic, Mark C Petrie und 8 weitere

JACC: Cardiovascular Interventions · 2025-03 · 18 (6) · 738-748

DOI: 10.1016/j.jcin.2024.11.036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Cardiovascular Interventions, 2025-03. Verfasst von Tayyab Shah und 19 weiteren Autor:innen. Beteiligte Einrichtung: The Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA; Yale Cardiovascular Research Group, New Haven, Connecticut, USA. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Aortic Valve Stenosis, Aortic Valve. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Aortic stenosis (AS) is the leading cause of valvular heart disease-related morbidity and mortality, but there are no medical treatments to slow its progression. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have pleiotropic effects which could be disease modifying in AS. OBJECTIVES: The purpose of this study was to determine if SGLT2i usage is associated with slower progression of AS. METHODS: A target trial emulation comparing the effect of the initiation of SGLT2i compared with no SGLT2i in patients with nonsevere AS was performed using retrospective electronic medical record data from the Yale New Haven Health System from January 2016 to September 2022. Patients with native aortic valve sclerosis or nonsevere AS with at least 12 months of echocardiographic follow-up were included. Patients were excluded if they had an estimated glomerular filtration rate 1 year before the index echocardiogram. The prespecified primary outcome was progression to severe AS. RESULTS: A total of 458 patients prescribed SGLT2i and 11,240 patients never prescribed SGLT2i were included. Patients were on SGLT2i for a median of 0.9 years. Patients on SGLT2i were younger and had higher rates of diabetes and chronic kidney disease. Patients on SGLT2i were more likely to have ejection fraction ≤40%. There were no differences between groups in baseline AS severity (66% sclerosis, 23% mild stenosis, and 11% moderate in overall cohort). Patients ever prescribed SGLT2i were less likely to progress to severe AS (HR: 0.61; 95% CI: 0.39-0.94; P = 0.03) with a progressively lower risk among patients on SGLT2i for >3, 6, and 12 months (HR: 0.54, 0.48, and 0.27, respectively). CONCLUSIONS: This retrospective, multicenter, observational study suggests that SGLT2i may slow the progression of nonsevere AS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsAortic Valve StenosisAortic ValveHumansMaleDisease ProgressionFemaleRetrospective StudiesAgedTime FactorsTreatment OutcomeRisk FactorsSeverity of Illness IndexAged, 80 and overMiddle AgedRisk AssessmentElectronic Health Records

Stichwörter der Autor:innen

aortic stenosiscomparative effectivenessprogressionsodium-glucose co-transporter 2 inhibitorstarget trial emulation

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • The Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA; Yale Cardiovascular Research Group, New Haven, Connecticut, USA.
  • Yale Cardiovascular Research Group, New Haven, Connecticut, USA.
  • Cornell University, Ithaca, New York, USA.
  • The Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Yale New Haven Hospital, New Haven, Connecticut, USA.
  • Northwell Health, Manhasset, New York, USA.

Zitieren

APA

Shah, T., Zhang, Z., Shah, H., Fanaroff, A. C., Nathan, A. S., Parise, H., Lutz, J., Sugeng, L., Bellumkonda, L., Redfors, B., Omerovic, E., Petrie, M. C., Vora, A. N., Fiorilli, P. N., Kobayashi, T., Ahmad, Y., Forrest, J. K., Giri, J. S., Herrmann, H. C., & Lansky, A. J. (2025). Effect of Sodium-Glucose Cotransporter-2 Inhibitors on the Progression of Aortic Stenosis. JACC: Cardiovascular Interventions, 18(6), 738-748. https://doi.org/10.1016/j.jcin.2024.11.036

Vancouver

Shah T, Zhang Z, Shah H, Fanaroff AC, Nathan AS, Parise H, et al. Effect of Sodium-Glucose Cotransporter-2 Inhibitors on the Progression of Aortic Stenosis. JACC: Cardiovascular Interventions. 2025;18(6):738-748. doi:10.1016/j.jcin.2024.11.036

BibTeX
@article{Shah2025,
  author = {Shah, Tayyab and Zhang, Zhiyuan and Shah, Haashim and Fanaroff, Alexander C and Nathan, Ashwin S and Parise, Helen and Lutz, John and Sugeng, Lissa and Bellumkonda, Lavanya and Redfors, Björn and Omerovic, Elmir and Petrie, Mark C and Vora, Amit N and Fiorilli, Paul N and Kobayashi, Taisei and Ahmad, Yousif and Forrest, John K and Giri, Jay S and Herrmann, Howard C and Lansky, Alexandra J},
  title = {Effect of Sodium-Glucose Cotransporter-2 Inhibitors on the Progression of Aortic Stenosis},
  journal = {JACC: Cardiovascular Interventions},
  year = {2025},
  volume = {18},
  number = {6},
  pages = {738--748},
  doi = {10.1016/j.jcin.2024.11.036}
}
Kostenlos starten →